Since antibodies against IFNα were present in a minority of patients with COVID-19, which is consistent with a previous study that anti-IFNα antibodies were present in approximately 12% of patients with COVID-19,4 IFNα reactivity alone may not explain the lack of ISG+ cells in the majority of patients with severe COVID-19. Here, IFNA1 is linked to COVID-19.